International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) – part I: upper facial wrinkles

Authors


  • Conflict of interest
    B. Ascher and B. Rzany have served as advisor, speaker and investigator for Galderma, Ipsen and Merz Pharma., S. Talarico, D. Cassuto, S. Escobar, P. Jaén and M. Viel are consultants for Galderma. D. Hexsel has served as consultant, speaker or researcher for the companies which own toxins. GD. Monheit is a consultant for Galderma and Ipsen.

Correspondence: B Ascher. E-mail:benjaminascher@wanadoo.fr

Abstract

Background  Azzalure (Galderma SA) is a newly approved European botulinum neurotoxin type A (BoNT-A). It is derived from Dysport (Ipsen Pharma), which has a long history of usages in various applications. Azzalure and Dysport are collectively referred to as BoNT-A (Speywood Unit) and are different from other BoNT-A preparations.

Objective  To provide consensus recommendations on the treatment of upper face wrinkles with BoNT-A (Speywood Unit).

Methods  The members of the International Board on Botulinum toxin Azzalure (IBBA) convened to develop consensus on the treatment of upper facial wrinkles based on their own extensive experience.

Results  The consensus recommendations address the general issues regarding treatment and provide specific guidelines on the anatomy, injection points, dose, injection technique and safety precautions concerning each common upper face indication. The recommended final concentration of BoNT-A (Speywood Unit) is 200 s.U/mL (10 s.U/0.05 mL) after reconstitution. For glabellar lines, the members recommend a total of five injection points with 10 s.U/point. For forehead wrinkles, the members recommend four to six injections into the frontalis with 5–10 s.U/point. For crow’s feet, the members recommend three injections per side with 5–10 s.U/point at the lateral part of the orbicularis oculi. For lateral eyebrow lift, the members recommend one point at each eyebrow tail and an additional one in each side of the frontalis with 5–10 s.U/point.

Conclusion  This guideline provides a framework for physicians who wish to perform safe and efficacious injection of BoNT-A (Speywood Unit).

Ancillary